A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients

Allison N. Grossberg,Lilia A. Koza,Aurélie Ledreux,Chad Prusmack,Hari Krishnan Krishnamurthy,Vasanth Jayaraman,Ann-Charlotte Granholm,Daniel A. Linseman
DOI: https://doi.org/10.1038/s41467-021-21040-7
IF: 16.6
2021-02-02
Nature Communications
Abstract:Abstract The COVID-19 pandemic affects more than 81 million people worldwide with over 1.7 million deaths. As the population returns to work, it is critical to develop tests that reliably detect SARS-CoV-2-specific antibodies. Here we present results from a multiplex serology test for assessing the antibody responses to COVID-19. In an initial large cohort, this test shows greater than 99% agreement with COVID-19 PCR test. In a second outpatient cohort consisting of adults and children in Colorado, the IgG responses are more robust in positive/symptomatic participants than in positive/asymptomatic participants, the IgM responses in symptomatic participants are transient and largely fall below the detection limit 30 days after symptom onset, and the levels of IgA against SARS-CoV-2 receptor binding domain are significantly increased in participants with moderate-to-severe symptoms compared to those with mild-to-moderate symptoms or asymptomatic individuals. Our results thus provide insight into serology profiling and the immune response to COVID-19.
multidisciplinary sciences
What problem does this paper attempt to address?